Walnut Allergy Across Europe: Distribution of Allergen Sensitization Patterns and Prediction of Severity.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
01 2021
Historique:
received: 12 05 2020
revised: 17 07 2020
accepted: 24 08 2020
pubmed: 12 9 2020
medline: 22 5 2021
entrez: 11 9 2020
Statut: ppublish

Résumé

Walnut allergy is common across the globe, but data on the involvement of individual walnut components are scarce. To identify geographical differences in walnut component sensitization across Europe, explore cosensitization and cross-reactivity, and assess associations of clinical and serological determinants with severity of walnut allergy. As part of the EuroPrevall outpatient surveys in 12 European cities, standardized clinical evaluation was conducted in 531 individuals reporting symptoms to walnut, with sensitization to all known walnut components assessed in 202 subjects. Multivariable Lasso regression was applied to investigate predictors for walnut allergy severity. Birch-pollen-related walnut sensitization (Jug r 5) dominated in Northern and Central Europe and lipid transfer protein sensitization (Jug r 3) in Southern Europe. Profilin sensitization (Jug r 7) was prominent throughout Europe. Sensitization to storage proteins (Jug r 1, 2, 4, and 6) was detected in up to 10% of subjects. The walnut components that showed strong correlations with pollen and other foods differed between centers. The combination of determinants best predicting walnut allergy severity were symptoms upon skin contact with walnut, atopic dermatitis (ever), family history of atopic disease, mugwort pollen allergy, sensitization to cat or dog, positive skin prick test result to walnut, and IgE to Jug r 1, 5, 7, or carbohydrate determinants (area under the curve = 0.81; 95% CI, 0.73-0.89). Walnut-allergic subjects across Europe show clear geographical differences in walnut component sensitization and cosensitization patterns. A predictive model combining results from component-based serology testing with results from extract-based testing and information on clinical background allows for good discrimination between mild to moderate and severe walnut allergy.

Sections du résumé

BACKGROUND
Walnut allergy is common across the globe, but data on the involvement of individual walnut components are scarce.
OBJECTIVES
To identify geographical differences in walnut component sensitization across Europe, explore cosensitization and cross-reactivity, and assess associations of clinical and serological determinants with severity of walnut allergy.
METHODS
As part of the EuroPrevall outpatient surveys in 12 European cities, standardized clinical evaluation was conducted in 531 individuals reporting symptoms to walnut, with sensitization to all known walnut components assessed in 202 subjects. Multivariable Lasso regression was applied to investigate predictors for walnut allergy severity.
RESULTS
Birch-pollen-related walnut sensitization (Jug r 5) dominated in Northern and Central Europe and lipid transfer protein sensitization (Jug r 3) in Southern Europe. Profilin sensitization (Jug r 7) was prominent throughout Europe. Sensitization to storage proteins (Jug r 1, 2, 4, and 6) was detected in up to 10% of subjects. The walnut components that showed strong correlations with pollen and other foods differed between centers. The combination of determinants best predicting walnut allergy severity were symptoms upon skin contact with walnut, atopic dermatitis (ever), family history of atopic disease, mugwort pollen allergy, sensitization to cat or dog, positive skin prick test result to walnut, and IgE to Jug r 1, 5, 7, or carbohydrate determinants (area under the curve = 0.81; 95% CI, 0.73-0.89).
CONCLUSIONS
Walnut-allergic subjects across Europe show clear geographical differences in walnut component sensitization and cosensitization patterns. A predictive model combining results from component-based serology testing with results from extract-based testing and information on clinical background allows for good discrimination between mild to moderate and severe walnut allergy.

Identifiants

pubmed: 32916320
pii: S2213-2198(20)30935-1
doi: 10.1016/j.jaip.2020.08.051
pii:
doi:

Substances chimiques

Allergens 0
Antigens, Plant 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

225-235.e10

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Sarah A Lyons (SA)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Electronic address: s.a.lyons-2@umcutrecht.nl.

Mareen R Datema (MR)

Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Thuy-My Le (TM)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Riccardo Asero (R)

Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.

Laura Barreales (L)

Clinical Epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Simona Belohlavkova (S)

Medical Faculty and Faculty Hospital Pilsen, Charles University, Pilsen, Czech Republic.

Frédéric de Blay (F)

Allergy Division, Chest Disease Department, Strasbourg University Hospital, University of Strasbourg, Strasbourg, France.

Michael Clausen (M)

Landspitali University Hospital, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Ruta Dubakiene (R)

Medical Faculty, Vilnius University, Vilnius, Lithuania.

Cristina Fernández-Perez (C)

Clinical Epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Philipp Fritsche (P)

Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.

David Gislason (D)

Landspitali University Hospital, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Karin Hoffmann-Sommergruber (K)

Medical University of Vienna, Department of Pathophysiology and Allergy Research, Vienna, Austria.

Monika Jedrzejczak-Czechowicz (M)

Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Łódź, Łódź, Poland.

Laurian Jongejan (L)

Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.

Marek L Kowalski (ML)

Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Łódź, Łódź, Poland.

Tanya Z Kralimarkova (TZ)

Clinical Centre of Allergology, Medical University of Sofia, Sofia, Bulgaria.

Jonas Lidholm (J)

Thermo Fisher Scientific, Uppsala, Sweden.

Nikolaos G Papadopoulos (NG)

Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece; Division of Infection, Immunity & Respiratory Medicine, Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom.

Bo Pontoppidan (B)

Thermo Fisher Scientific, Uppsala, Sweden.

Todor A Popov (TA)

University Hospital Sv. Ivan Rilski, Sofia, Bulgaria.

Nayade Del Prado (ND)

Clinical Epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Ashok Purohit (A)

Allergy Division, Chest Disease Department, Strasbourg University Hospital, Strasbourg, France.

Isabel Reig (I)

Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Suranjith L Seneviratne (SL)

Institute of Immunity and Transplantation, University College London, London, United Kingdom.

Athanasios Sinaniotis (A)

Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.

Emilia Vassilopoulou (E)

Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.

Serge A Versteeg (SA)

Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.

Stefan Vieths (S)

Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.

Aeilko H Zwinderman (AH)

Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Paco M J Welsing (PMJ)

Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

E N Clare Mills (ENC)

Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.

Barbara K Ballmer-Weber (BK)

Medical Faculty, Vilnius University, Vilnius, Lithuania; Faculty of Medicine, University of Zürich, Zürich, Switzerland; Clinic for Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, Switzerland.

André C Knulst (AC)

Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Montserrat Fernández-Rivas (M)

Allergy Department, Hospital Clinico San Carlos, IdISSC, ARADyAL, Madrid, Spain.

Ronald Van Ree (R)

Department of Experimental Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands; Department of Otorhinolaryngology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH